MediWound reported second quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, and reaffirmed full-year revenue guidance of $24 million to $26 million. The company said its EscharEx Phase III VLU trial is on track for interim sample size reassessment and enrollment completion by the end of the first quarter of 2027, and an updated U.S. market assessment now estimates annual peak sales of $1.05 billion for EscharEx across multiple chronic wound indications. For NexoBrid, Vericel reported its strongest quarter since launch with record revenue, hospital unit sales, and ordering centers, and MediWound entered a master service agreement with Vericel covering NexoBrid and next-generation product development. MediWound expects to begin recognizing revenue under the MSA in the second half of 2026, and it continues to advance a room temperature stable formulation of NexoBrid supported by $18.3 million in funding from the Department of War. The company reported a net loss of $7.4 million, or $0.57 per share, for the second quarter, compared with a net loss of $13.3 million, or $1.23 per share, in the prior year period.
Vericel Corp OrdVericel reported record revenue, hospital unit sales, and ordering centers for NexoBrid, indicating strong end-customer demand.
Mediwound Ltd